JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy

  • 0Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing 400044, China.
Acs Applied Materials & Interfaces +

|

June 13, 2024

|

June 13, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study introduces novel nanoparticles that reduce cholesterol and reactive oxygen species (ROS) in atherosclerotic plaques. This dual-action approach offers a promising new therapy for atherosclerosis (AS).

Area Of Science

  • Biomedical Engineering
  • Nanotechnology
  • Cardiovascular Research

Background

  • Atherosclerotic plaques are characterized by high cholesterol and oxidative stress from reactive oxygen species (ROS), driving inflammation.
  • Current therapies struggle to address these multiple pro-inflammatory factors simultaneously.
  • Developing strategies to remove cholesterol and scavenge ROS is crucial for effective atherosclerosis (AS) treatment.

Purpose Of The Study

  • To construct macrophage membrane-encapsulated biomimetic nanoparticles (MM@DA-pCD@MTX) for simultaneous cholesterol removal and ROS scavenging.
  • To investigate the therapeutic potential of MM@DA-pCD@MTX in alleviating cholesterol deposition and oxidative stress in atherosclerotic lesions.
  • To evaluate the targeted drug delivery and pharmacokinetic advantages of MM-functionalized nanoparticles for AS treatment.

Main Methods

  • Construction of macrophage membrane-encapsulated biomimetic nanoparticles (MM@DA-pCD@MTX).
  • Utilizing β-cyclodextrin (β-CD) and methotrexate (MTX) to induce cholesterol efflux and inhibit foam cell formation.
  • Incorporating dopamine (DA) for reactive oxygen species (ROS) scavenging.
  • Leveraging macrophage membrane (MM) for targeted delivery to atherosclerotic plaques.

Main Results

  • MM@DA-pCD@MTX effectively alleviated cholesterol deposition via reverse cholesterol transport.
  • The nanoparticles successfully scavenged overaccumulated ROS, reducing oxidative stress.
  • MTX upregulated key genes (ABCA1, CYP27A1, SR-B1) involved in cholesterol metabolism.
  • β-CD enhanced cholesterol crystal solubility, and DA preserved ROS scavenging ability.
  • MM functionalization enabled targeted delivery, prolonged circulation time, and increased drug half-life.

Conclusions

  • MM@DA-pCD@MTX is a potent, multifunctional therapeutic platform for atherosclerosis (AS) treatment.
  • The nanoparticles demonstrate high biosafety and efficacy in addressing the complex pathophysiology of AS.
  • This biomimetic nanoparticle approach offers a promising strategy for managing cholesterol deposition and oxidative stress in AS.

Keywords: